VSY Biotechnology, Gold Sponsor of the ESCRS iNovation® Day, Shares Visions for the Next 5 Years in Ophthalmic Market
The 40th Congress of the European Society of Cataract and Refractive Surgery (ESCRS) took place between September 16-20 at the Milano Convention Centre in Milan, Italy. The highlight of this year’s congress was iNovation® Day, a first-of-its-kind event marking a new annual tradition in the ESCRS community, thanks to the organizing committee by Oliver Findl, President of the ESCRS, Roberto Bellucci, Jose Güell, Rudy Nuijts, Burkhard Dick, Thomas Kohnen, Filomena Ribeiro, and Paul Rosen.
This special event brought together clinical and business experts from across Europe and other parts of the world. Sessions focused on the most urgent clinical needs and barriers to success in anterior segment care—and how the latest technology innovations may address those barriers and clinical needs within the next 5 years.
The event featured a balanced mix of doctors and global executives from established and emerging public and private companies.
Efe Can, MD, Global Innovation and Medical Affairs Director at VSY Biotechnology, commented on what to expect in the Ophthalmic Industry for the next 5 years at the round table with other industry players such as Alcon, Staar Surgical, BVI, Johnson & Johnson Vision, and Zeiss.
Current major economic interruptions led by Covid-19 and recent disruptions to energy supplies from the war in Ukraine were one of the main discussion topics during the session on companies’ innovation strategies.
Efe Can, MD highlighted the importance of being an agile company to adapt to the changing macro-economic environment while keeping sustainable growth. He added that the key to ensuring a sustainable growth in the era of crisis is being a self-sufficient company. VSY Biotechnology has taken several crucial steps to that end to become a self-sufficient company from the aspects of supply safety and energy sustainability to packaging.
